Sun Pharma Q3 Results: Net profit up 15%; revenue at Rs 13,675 crore

Sun Pharma Q3 Results: Sun Pharmaceutical Industries connected Friday said its consolidated nett net accrued 15 per cent on-year to Rs 2,903 crore successful the December quarter, riding connected robust income crossed geographies. The cause large had reported a nett net of Rs 2,524 crore successful the October-December 4th of past fiscal.

Total gross from operations roseate to Rs 13,675 crore successful the 3rd 4th compared to Rs 12,381 crore successful the year-ago period, Sun Pharma said successful a regulatory filing.

The institution said its committee has declared an interim dividend of Rs 10.5 per stock for the twelvemonth FY25 against Rs 8.50 per stock interim dividend for the erstwhile year.

"Our show successful the 4th showed all-round improvement. Product income successful Global Specialty crossed 1/5th of wide sales," Sun Pharma Chairman and Managing Director Dilip Shanghvi said.

"Our marketplace stock summation successful India has been driven by industry-leading measurement growth. Emerging Markets demonstrated beardown show successful spite of currency challenges crossed geographies," helium added.

All the company's businesses stay well-positioned for the future, Shanghvi stated.

The Mumbai-based cause shaper said its formulation income successful India stood astatine Rs 4,300 crore successful the December quarter, a maturation of 13.8 per cent implicit the aforesaid play past fiscal and accounting for astir 32 per cent of full consolidated sales.

Formulation income successful the US were astatine USD 474 cardinal for the 3rd quarter, a marginal dip arsenic compared with the 3rd 4th of past fiscal and accounting for astir 30 per cent of the full consolidated sales.

Formulation income successful the emerging markets stood astatine USD 277 cardinal successful the 3rd quarter, a year-on-year maturation of 10 per cent and accounting for astir 17 per cent of full consolidated sales.

Similarly, formulation income successful the Rest of World (ROW) markets, excluding India, the US and Emerging Markets, stood astatine USD 259 cardinal successful Q3FY25, a year-on-year maturation of 21 per cent against the preceding fiscal.

External income of API (Active Pharmaceutical Ingredient) were Rs 568 crore successful Q3FY25, increasing by 21.8 per cent implicit Q3 past year.

Sun Pharma shares ended 0.12 per cent little astatine Rs 1,743.10 apiece connected the BSE.